Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001733 · ClinicalTrials.gov registry record
Screening for Studies on Retinovascular Diseases
A clinical trial, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 2,000
- Enrollment target
NCT00001733: Completed study, sponsored by National Eye Institute (NEI).
NCT00001733 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 2,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001733 has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 2,000 participants
- Enrollment target
Study Summary
This screening protocol is designed to help recruit patients for National Eye Institute (NEI) studies of the retina, such as diabetic retinopathy and macular degeneration. Patients must meet the specific criteria of a research study, and this protocol serves as a first step for admitting patients to a retinal disease study. Candidates will undergo a medical history and comprehensive eye examination. The eye examination includes dilation of the pupils to fully examine the retina. In some studies, photographs of the eye are required. This is done using fluorescein angiography. In this procedure, a dye called sodium fluorescein is injected into the blood stream through a vein. After the dye reaches the blood vessels of the eye, photographs are taken of the retina. Other diagnostic procedures may include physical examination, questionnaires, routine laboratory tests and other standard or specialized tests, as needed. When the screening is completed, patients will be informed of their options to participate in a study. Patients who are ineligible for a current study will be informed of alternative treatments or options. No treatment is offered under this protocol.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 1998-03-06 |
| Est. Completion | 2008-07-02 |
What the finished NCT00001733 record still lists
NCT00001733 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00001733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001733 about?
NCT00001733 is a clinical study titled "Screening for Studies on Retinovascular Diseases". This screening protocol is designed to help recruit patients for National Eye Institute (NEI) studies of the retina, such as diabetic retinopathy and macular degeneration. Patients must meet the specific criteria of a research study, and this protocol serves as a first step for admitting patients to...
What is the current status of trial NCT00001733?
This trial is currently completed. The enrollment target is 2,000 participants. The study started on 1998-03-06. Estimated completion is 2008-07-02.
Who is sponsoring clinical trial NCT00001733?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI